What happened, in summary

Emily Bannister was 46, a physician, and a mother of 3 when breathing symptoms led to a Stage IV lung cancer diagnosis. She first noticed wheezing while lying down, shortness of breath, and a fast heart rate with stairs. An urgent-care X-ray looked like pneumonia, but antibiotics did not help and follow-up imaging worsened. CT showed enlarged lymph nodes and widespread changes in her lungs. Bronchoscopy biopsies found lung adenocarcinoma throughout sampled areas. Although the cancer was Stage IV, it was contained within her chest cavity. Her pulmonologist pushed for biomarker testing, and Emily learned that the tumor was EGFR Exon 19-positive with no other driver mutations reported. Instead of chemotherapy, she was offered a once-daily targeted pill and entered a clinical trial. When breathing worsened just before the planned start, her team helped her begin treatment 1 day early. Within about a week, she was off oxygen, could lie on her right side again, and soon returned to tap dancing. At 2 months, the response was excellent and the lymphatic spread was gone. Emily later passed away on March 14, 2023 from complications caused by Stage IV lung cancer. She used her story to support lung cancer research and EGFR-focused advocacy.